Clinical trials: Chronic Obstructive Pulmonary Diseases
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and emphysema/ chronic…
- Trial name
- NCT02722304
- Testing
- ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 7 people
- Sponsor
- Baxalta now part of Shire
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma
This study is a multi-centre, randomised, double-blind, placebo-controlled (with rescue medication), two period crossover study in subjects with persistent uncontrolled asthma, currently not treated with an inhaled corticosteroid…
- Trial name
- NCT02567708
- Testing
- GSK2269557 DPI
- Where
- 12 sites in Germany
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)
The purpose of the study is to evaluate Real-World Effectiveness of a Triple Combination Beclometasone Diproprionate/Formoterol Fumarate/Glycopyrronium Bromide (BDP/FF/GB) in a Single Pressurised Metered Dose Inhaler (Trimbow®…
- Trial name
- TRIPHY (NCT06480890)
- Where
- 19 sites in China
- Volunteers
- 362 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.
- Trial name
- SUMIRE (NCT01069289)
- Testing
- Budesonide/formoterol (Symbicort Turbuhaler), Formoterol (Oxis Turbuhaler)
- Where
- 119 sites in India, Japan and 7 more
- Volunteers
- 1,293 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions
The study evaluates the effect of GSK2256294 exposure at steady state on pulmonary artery systolic pressure (PASP) in healthy volunteers, under hypoxic conditions, after 7 days of dosing.
- Trial name
- NCT02262689
- Testing
- GSK2256294
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the long-term safety of Ba253BINEB. Secondarily the long-term efficacy of Ba253BINEB is also investigated.
- Trial name
- NCT02182635
- Testing
- Ba253BINEB
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The study is a Phase II, multicenter, double-blind, randomized, parallel, placebo-controlled clinical trial designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of TQC2938 in patients with…
- Trial name
- NCT06789289
- Testing
- TQC2938 injection
- Where
- 40 sites in China
- Volunteers
- 256 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Chronic Obstructive Pulmonary Disease, COPD
Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease
This purpose of this study is to assess the safety of ramelteon, once daily (QD), in subjects with chronic obstructive pulmonary disease.
- Trial name
- NCT00672802
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Takeda
Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and…
- Trial name
- PROSPERO (NCT05742802)
- Testing
- Tozorakimab 1, Tozorakimab 2
- Where
- 335 sites in United States, Argentina and 35 more
- Volunteers
- 1,713 people
- Sponsor
- AstraZeneca
COPD, Dyspnea
Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients
Dyspnea is the most common symptom limiting the ability of COPD patients to perform activities of daily living. Although there has been research involving the benefit of providing Non Invasive Ventilation (NIV) during exercise to…
- Trial name
- NCT03349437
- Testing
- Vitabreath Device, Pursed Lip Breathing
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Philips Respironics
Multiple Myeloma
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess the safety and benefits of the investigational study drug, KW-2478, when given with bortezomib (Velcade®), a drug approved for the treatment of Multiple Myeloma (MM).
- Trial name
- NCT01063907
- Testing
- KW-2478, Bortezomib
- Where
- 26 sites in United States, Philippines and 1 more
- Volunteers
- 95 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Chronic Obstructive Pulmonary Disease (COPD)
Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control
This study will compare the efficacy of indacaterol versus placebo (i.e., rescue medication only) and tiotropium in patients with Chronic Obstructive Pulmonary Disease (COPD) who have not received maintenance COPD medication for…
- Trial name
- INITIATE (NCT01715311)
- Testing
- Indacaterol, Tiotropium
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment
Patients with moderate COPD as defined by GOLD guidelines constitute almost 46% to 54% of all diagnosed COPD patients. Yet limited data exists on characterizing this study population in terms of drug therapy patterns and…
- Trial name
- NCT01395875
- Testing
- Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC), Anticholinergics (AC)
- Volunteers
- 2,849 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Exacerbation Study
This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks
- Trial name
- INVIGORATE (NCT00845728)
- Testing
- Indacaterol 150 µg, Tiotropium
- Where
- 423 sites in Argentina, Australia and 38 more
- Volunteers
- 3,439 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD
The purpose of this study is to assess if 12 weeks' treatment with GSK573719 Inhalation Powder is safe and effective compared with placebo or no active drug intake, when administered once-daily in subjects with Chronic…
- Trial name
- NCT01387230
- Testing
- GSK573719
- Where
- 27 sites in United States, Germany and 1 more
- Volunteers
- 206 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
The purpose of this study is the evaluate the safety and tolerability of repeat dosing of the combination of inhaled GSK233705 and GW642444 administered once-daily in subjects with COPD.
- Trial name
- NCT00749411
- Testing
- GSK233705/GW642444
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared…
- Trial name
- NCT02796677
- Testing
- Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg)
- Where
- 163 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,595 people
- Sponsor
- AstraZeneca
Remote Patient Monitoring in COPD Patients
Compare the Effect of a Remote Monitoring System Using the EXACT Tool to Reduce Hospitalizations Due to Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. EXACT = Exacerbations of Chronic Pulmonary Disease Tool.
The purpose of this pilot study is to evaluate a remote patient monitoring (RPM) system using a daily PRO tool (EXACT = Exacerbations of Chronic Pulmonary Disease Tool), in preventing hospitalization from Chronic Obstructive…
- Trial name
- PREMIERE (NCT01744028)
- Testing
- Remote Patient Monitoring, Usual care
- Where
- 20 sites in Spain, Sweden
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19, Coronavirus Infections
Audio Data Collection for Identification and Classification of Coughing
An open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.
- Conditions
- COVID-19, Coronavirus Infections, Hay Fever, Asthma
- Trial name
- NCT04326309
- Where
- United States
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- HealthMode Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.